natgillin/translations-raw huggingface dataset:
It can be used to treat aspergillosis in cockatoos, parrots, parakeets, budgerigars, falcons, hawks, owls and swans, and also to treat candidiasis in cockatoos, parrots, parakeets and budgerigars. 
Može se koristiti za liječenje aspergilze u kakadua, papiga, papigica, australskih papigica, sokola, jastrebova, sova i labudova, te također za liječenje kandidijaze u kakadua, papiga, papigica i australskih papigica.
In the case of accidental ingestion the mouth should be rinsed, medical advice sought immediately and the package leaflet or label shown to the doctor. 
U slučaju da se nehotice proguta, usta treba isprati vodom te odmah potražiti pomoć liječnika i pokazati mu uputu o veterinarsko-medicinskom proizvodu ili etiketu proizvoda.
When handling birds infected with aspergillosis, latex gloves and a mask should be worn to prevent the disease being transmitted to the handler. 
Budući da postoji rizik od prijenosa aspergiloze na ljude, treba nositi lateks rukavice i maske prilikom rukovanja pticama zaraženima aspergilozom.
It is available as a solution to be given by mouth. 
Dostupan je kao peroralna otopina.
What is the risk associated with Fungitraxx? 
Koji su rizici povezani s proizvodom Fungitraxx?
Hands and exposed skin should be washed after using Fungitraxx. 
Nakon primjene proizvoda Fungitraxx potrebno je oprati ruke i izloženu kožu.
For aspergillosis, birds were included if the presence of Aspergillus fungi in air sacs was confirmed and, for candidiasis, birds were included if clinical signs of candidiasis were present and infection was confirmed. 
U slučaju aspergiloze, ptice su uključene u ispitivanje ako je prisutnost gljivica Aspergillus potvrđena u zračnim vrećicama.
Other information about Fungitraxx: 
Druge informacije o veterinarsko-medicinskom proizvodu Fungitraxx:
What is Fungitraxx? 
Što je Fungitraxx?
Why has Fungitraxx been approved? 
Zašto je Fungitraxx odobren?
What benefit has Fungitraxx shown during the studies? 
Koje su koristi proizvoda Fungitraxx utvrđene tijekom ispitivanja?
What is Fungitraxx used for? 
Za što se Fungitraxx koristi?
How does Fungitraxx work? 
Na koji način Fungitraxx djeluje?
How has Fungitraxx been studied? 
Kako se Fungitraxx ispitivao?
If you take more than you should 
Ako uzmete više nego što ste trebali
Invasive procedure was performed between Days 9 and 14. 
Invazivni postupak proveden je između 9. i 14. dana.
- Use reliable methods of contraception while you are taking Mulpleo. 
- Koristite pouzdane metode kontracepcije dok uzimate Mulpleo.
You can take it with food or between meals. 
Može se uzimati uz obrok ili između obroka.
- Tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby. 
- Obavijestite svog liječnika ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete.
Mulpleo should not be taken for more than 7 days. 
Mulpleo se ne smije uzimati dulje od 7 dana.
The risk may be increased due to an invasive procedure. 
Taj rizik može biti povećan kod invazivnog postupka.
Patients with body weight <45 Kg 
Bolesnici tjelesne težine < 45 kg
Do not give this medicine to children or adolescents under the age of 18 years, because the medicine has not been studied in children and adolescents. 
Nemojte davati ovaj lijek djeci ili adolescentima mlađima od 18 godina zato što lijek nije ispitan u djece i adolescenata.
Human plasma protein binding ratio is ≥ 99.9%. 
Omjer vezanja za proteine ljudske plazme je ≥ 99,9%.
Recommended dose: take one tablet once a day, at the same time each day, for seven days only. 
Preporučena doza: uzmite jednu tabletu jednom dnevno, svakog dana u isto vrijeme, tijekom samo sedam dana.
If you forget to take a tablet 
Ako ste zaboravili uzeti tabletu
It can be taken with or without food. 
Uzima se s hranom ili bez nje.
Total - n - Median (days) - (Q1, Q3) - P value [a] 
Ukupno - n - Medijan (dani) - (Q1, Q3) - P vrijednost [a]
Your treatment will start at least 8 days before your surgery or procedure. 
S liječenjem ćete započeti najmanje 8 dana prije kirurškog zahvata ili nekog sličnog postupka.
Therefore, a risk to the breast-feeding child cannot be excluded. 
Stoga se rizik za dojenče ne može isključiti.
What Mulpleo is and what it is used for 
Što je Mulpleo i za što se koristi
What you need to know before you take Mulpleo 
Što morate znati prije nego počnete uzimati Mulpleo
If possible, show them the pack, or this leaflet. 
Po mogućnosti, pokažite im pakiranje ili ovu uputu o lijeku.
Comparison with placebo [b]: Difference of proportion (95% CI) 
Usporedba s placebom [b]: razlika udjela (95% CI)
Signs of a blood clot: look out for any of the signs below: 
Znakovi pojave krvnog ugruška: pazite na bilo koji od niže navedenih znakova:
• sudden shortness of breath, especially with sharp pain in the chest or rapid breathing 
• iznenadni nedostatak zraka, osobito uz oštar bol u prsnom košu i ubrzano disanje
If you miss a tablet of Mulpleo, take it as soon as you remember on the same day. 
Ako propustite tabletu lijeka Mulpleo, uzmite je čim se sjetite istog dana.
Take the tablet with a liquid and swallow it whole. 
Tabletu uzmite s tekućinom i progutajte je cijelu.
If a dose is missed it should be taken as soon as possible. 
Ako se propusti, dozu se mora uzeti što prije.
Do not take Mulpleo: - if you are allergic to lusutrombopag or any of the other ingredients of this medicine (listed in section 6 under ‘What Mulpleo contains'). 
Nemojte uzimati Mulpleo: - ako ste alergični na lusutrombopag ili neke druge sastojke ovog lijeka (navedene u dijelu 6 pod „Što Mulpleo sadrži“).
The effect of Mulpleo during pregnancy is not known. 
Učinak lijeka Mulpleo tijekom trudnoće nije poznat.
The safety and efficacy of lusutrombopag in children and adolescents (< 18 years of age) have not been established. 
Sigurnost i djelotvornost lusutrombopaga u djece i adolescenata (u dobi < 18 godina) nisu ustanovljene.
Do not chew, break, or crush the tablet. 
Nemojte žvakati, lomiti ili drobiti tabletu.
If you stop taking Mulpleo 
Ako prestanete uzimati Mulpleo
Do not stop taking Mulpleo without talking to your doctor and do not take Mulpleo for more than 7 days. 
Nemojte prestati uzimati Mulpleo a da prethodno niste o tome razgovarali s liječnikom i nemojte ga uzimati dulje od 7 dana.
The medicine helps to increase the number of platelets in your blood. 
Ovaj lijek pomaže da se poveća broj krvnih pločica u krvi.
• Risk Management Plan (RMP) 
PRIMJENU LIJEKA Plan upravljanja rizikom (RMP)
Higher risk of blood clots 
Veći rizik od krvnih ugrušaka
No dosage adjustment is expected for these patients. 
Ne očekuje se da će biti potrebna prilagodba doze u ovih bolesnika.
Pharmacokinetics in subpopulations 
Farmakokinetika u populacijskim podskupinama
The recommended dose is 3 mg lusutrombopag once daily for 7 days. 
Preporučena doza je 3 mg lusutrombopaga jedanput na dan tijekom 7 dana.
Do not change the dose or schedule for taking Mulpleo unless your doctor or pharmacist tells you to. 
Nemojte mijenjati dozu ni raspored uzimanja lijeka Mulpleo, osim ako Vam je tako rekao liječnik ili ljekarnik.
What Mulpleo looks like and contents of the pack 
Kako Mulpleo izgleda i sadržaj pakiranja
It is given to adults who have low numbers of platelets because of chronic liver disease. 
Daje se odraslim osobama koje imaju nizak broj krvnih pločica zbog kronične bolesti jetre.
If you have taken more Mulpleo than you should, talk to your doctor or go to the hospital. 
Ako ste uzeli više lijeka Mulpleo nego što ste trebali, obratite se liječniku ili otiđite u bolnicu.
Paediatric population No pharmacokinetic data have been obtained in children. 
Nisu dobiveni farmakokinetički podaci u djece.
Mulpleo is used to reduce the risk of bleeding during surgery and other procedures (including tooth extractions and endoscopy). 
Mulpleo primjenjuje se za smanjenje rizika od krvarenja tijekom kirurškog zahvata i drugih sličnih postupaka (uključujući vađenje zuba i endoskopiju).
Platelet counts should be measured frequently and the condition of patients should be observed closely. 
Broj trombocita mora se često mjeriti, a stanje bolesnika pažljivo promatrati.
- If you do become pregnant during treatment with Mulpleo, tell your doctor immediately. 
- Ako zatrudnite za vrijeme liječenja lijekom Mulpleo, odmah o tome obavijestite liječnika.
Age, gender and race 
Dob, spol i etnička pripadnost
Lusutrombopag is rarely excreted into urine (approximately 1%). 
Lusutrombopag se rijetko izlučuje mokraćom (približno 1%).
Study drug was administered orally for up to 7 days. 
Ispitivani lijek primjenjivao se peroralno do 7 dana.
Co-administration with interferon preparations 
Istodobna primjena pripravaka interferona
Lusutrombopag is not recommended during pregnancy and in women of child-bearing potential not using contraception. 
Lusutrombopag se ne preporučuje tijekom trudnoće i u žena reproduktivne dobi koje ne koriste kontracepciju.
Certain people may have a higher risk of blood clots, including people with liver disease, and medicines like Mulpleo could make this problem worse. 
U nekih osoba može biti prisutan veći rizik od nastanka krvnih ugrušaka, što uključuje i osobe s kroničnom bolešću jetre, a lijekovi poput lijeka Mulpleo mogu pogoršati taj problem.
Pharmacotherapeutic group: Antihemorrhagics, other systemic hemostatics, ATC code: B02BX07 
Farmakoterapijska skupina: antihemoragici, drugi sistemski hemostatici, ATK oznaka: B02BX07 Mehanizam djelovanja
INFORMATION IN BRAILLE Mulpleo 
16. PODACI NA BRAILLEOVOM PISMU Mulpleo
You may be monitored for side effects associated with excessive platelets such as blood clots (see section 2, ‘Warnings and precautions', and section 4, ‘Possible side effects'). 
Možda će Vas pratiti zbog nuspojava povezanih s prevelikim brojem krvnih pločica, kao što su krvni ugrušci (pogledajte dio 2, „Upozorenja i mjere opreza“ te dio 4, „Moguće nuspojave“).
Platelets are blood components that help the blood to clot and so prevent bleeding. 
Krvne pločice su sastavni dio krvi i sudjeluju u njezinom zgrušavanju te tako sprječavaju krvarenje.
Since the protein-binding rate in serum of lusutrombopag is high, haemodialysis is not thought to be effective. 
Budući da je stopa vezanja lusutrombopaga za proteine u serumu visoka, smatra se da hemodijaliza neće biti učinkovita.
LUSU = lusutrombopag; Q1 = 25th percentile; Q3 = 75th percentile [a] P-value was calculated by the van Elteren test with platelet transfusion status as stratum. 
LUSU = lusutrombopag; Q1 = 25. percentil; Q3 = 75. percentil [a] P-vrijednost izračunana je van Elterenovim testom uz stratifikaciju prema transfuziji trombocita.
• swelling, pain, heat, redness, or tenderness in your leg 
• oticanje, bol, toplina, crvenilo ili osjetljivost u nozi
If you have severe liver disease, tell your doctor before taking Mulpleo. 
Ako imate tešku bolest jetre, obavijestite o tome liječnika prije uzimanja lijeka Mulpleo.
No dosage adjustment is necessary in patients 65 years of age or older (see section 5.2). 
Nije potrebna prilagodba doze u bolesnika u dobi od 65 ili više godina (vidjeti dio 5.2).
Mulpleo is supplied in aluminium blisters in a carton containing 7 film-coated tablets. 
Mulpleo se isporučuje u aluminijskim blisterima u kartonskoj kutiji koja sadrži 7 filmom obloženih tableta.
In rats, lusutrombopag and its metabolites are excreted in milk, and the concentrations in milk decreased as with those in plasma. 
U štakora se lusutrombopag i njegovi metaboliti izlučuju u mlijeko, a njihove se koncentracije u mlijeku smanjuju kao i one u plazmi.
Other medicines and Mulpleo Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
The mean (% coefficient of variation) apparent volume of distribution during the terminal phase of lusutrombopag in healthy adult subjects (n = 16) was 39.5 L (23.5%). 
Srednja vrijednost (% koeficijenta varijacije) prividnog volumena distribucije tijekom terminalne faze lusutrombopaga u zdravih odraslih ispitanika (n = 16) iznosila je 39,5 l (23,5%).
Eight lusutrombopag-treated subjects and 2 placebo-treated subjects received less than 7 days of treatment as they met the criterion for a responder prior to Day 7. 
Osam ispitanika liječenih lusutrombopagom i 2 ispitanika koja su dobivala placebo primala su terapiju kraće od 7 dana jer su zadovoljili kriterij za terapijski odgovor prije 7. dana.
In addition, although no dose adjustment is required in these subjects, platelet count should be measured at least once approximately 5 days after the first dose and as necessary thereafter. 
Osim toga, iako u tih osoba nije potrebna prilagodba doze, potrebno je odrediti broj trombocita barem jedanput približno 5 dana nakon prve doze, a poslije po potrebi.
All 3 received 7 days of treatment with lusutrombopag. 
Sva 3 ispitanika primila su 7-dnevnu terapiju lusutrombopagom.
Geometric mean of t1/2 (% coefficient of variation), was 38.3 hours (18.7%) after multiple oral dose of 3 mg lusutrombopag. 
Geometrijska sredina t1/2 (% koeficijenta varijacije) iznosila je 38,3 sata (18,7%) nakon višekratnog peroralnog doziranja lusutrombopaga od 3 mg.
The efficacy and safety of lusutrombopag have not been established when administered before laparotomy, thoracotomy, open-heart surgery, craniotomy or excision of organs. 
Djelotvornost i sigurnost lusutrombopaga nisu ustanovljene kad se primjenjivao prije laparotomije, torakotomije, otvorene operacije srca, kraniotomije ili ekscizije organa.
Mulpleo should be used with contraception (see sub-section Pregnancy and section 5.3). 
Uz Mulpleo mora se uzimati kontracepcija (vidjeti potpoglavlje Trudnoća i dio 5.3).
Therefore, a potential interaction with either P-gp or BCRP inhibitors cannot be excluded, but no dose adjustment is necessary at the recommended clinical dosage of 3 mg in adults. 
Stoga se ne može isključiti mogućnost interakcije s inhibitorima P-gp-a ili BCRP-a, no u preporučenoj kliničkoj dozi od 3 mg u odraslih nije potrebna prilagodba doze.
There is no specific antidote for lusutrombopag overdose. 
Ne postoji određeni antidot za predoziranje lusutrombopagom.
A double dose should not be taken to make up for a missed dose. 
Ne smije se uzeti dvostruka doza kako bi se nadoknadila ona propuštena.
OPA/Aluminium foil/PVC film blister with push through aluminium lidding foil, packed in a cardboard box. 
Blister OPA/aluminijska folija/PVC film zatvoren aluminijskom folijom koja se otvara na potisak, pakiran u kartonskoj kutiji.
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1348 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/18/1348
PHARMACEUTICAL FORM AND CONTENTS 7 film-coated tablets 
OBLIK I SADRŽAJ 7 filmom obloženih tableta
What Mulpleo contains - The active substance is lusutrombopag. 
Što Mulpleo sadrži - Djelatna tvar je lusutrombopag.
Overdose may induce an excessive increase of platelet counts, and it may subsequently provoke a medically susceptible state to cause thrombosis and thromboembolism. 
Predoziranje može potaknuti prekomjerno povećanje broja trombocita te posljedično izazvati medicinsko stanje koje može uzrokovati trombozu i tromboemboliju.
Lusutrombopag should only be used in such patients if the expected benefit outweighs the expected risks (see sections 4.2 and 5.2). 
Lusutrombopag se u takvih bolesnika smije primjenjivati samo ako je očekivana korist veća od očekivanih rizika (vidjeti dijelove 4.2 i 5.2).
[b] Cochran-Mantel-Haenszel test with baseline platelet count as stratum. 
[b] Cochran-Mantel-Haenszelov test sa stratifikacijom prema početnom broju trombocita.
In addition to subjects who received platelet transfusion, subjects who did not receive an invasive procedure regardless of the reason were considered as receiving platelet transfusion. 
Uz ispitanike koji su primili transfuziju trombocita, ispitanici u kojih nije proveden invazivni postupak bez obzira na razlog smatrani su ispitanicima koji su primili transfuziju trombocita.
Lusutrombopag is absorbed with a peak concentration occurring 6 to 8 hours after oral administration. 
Nakon apsorpcije lusutrombopag postiže vršnu koncentraciju 6 - 8 sati nakon peroralne primjene.
In the analysis for pooled data, study was added as a stratum. 
U analizi objedinjenih podataka, dodana je stratifikacija prema ispitivanju.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. 
U nekliničkim ispitivanjima zapaženi su učinci samo pri izloženosti dozama koje su znatno više od maksimalno dopuštenih u ljudi, što ukazuje na njihov mali značaj za kliničku primjenu.
Lusutrombopag should be used when risk for bleeding is considered to be high according to clinical laboratory test values such as platelet counts and of the coagulation-fibrinolysis system, clinical symptoms and type of invasive procedure. 
Lusutrombopag treba primijeniti kad se rizik od krvarenja smatra visokim prema rezultatima kliničkih laboratorijskih testova kao što su broj trombocita i vrijednosti parametara sustava koagulacije i fibrinolize, kliničkim simptomima i vrsti invazivnog postupka.
• pain in the abdomen (tummy), swollen abdomen, blood in your stools. 
• bol u trbuhu (abdomenu), otečen trbuh, krv u stolici.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. sadrži zanemarive količine natrija.
In the placebo group, 94/107 subjects (87.9%) received the study drug for 7 days. 
U skupini koja je primala placebo, 94/107 ispitanika (87,9%) primalo je ispitivani lijek 7 dana.
How to take Mulpleo 
Kako uzimati Mulpleo
Thus, the data from the toxicology program in these animals do not present potential adverse effects related to exaggerated pharmacology in humans. 
Stoga podaci iz programa toksikoloških ispitivanja u ovih životinja ne predstavljaju moguće nuspojave povezane s pojačanim farmakodinamičkim učincima lusutrombopaga u ljudi.
Use in patients with chronic liver disease undergoing invasive procedures 
Primjena u bolesnika s kroničnom bolešću jetre u kojih se provode invazivni postupci
The pharmacokinetic parameters in patients with chronic liver disease are shown in Table 6. 
Farmakokinetički parametri u bolesnika s kroničnom bolešću jetre prikazani su u tablici 6.
• Blood clot in the liver (portal vein thrombosis) 
• krvni ugrušak u jetri (tromboza portalne vene) • osip.
These patients should be clinically monitored when treated with lusutrombopag. 
Te je bolesnike potrebno klinički pratiti kod liječenja lusutrombopagom.
Meanwhile, the short thoracolumbar supernumerary ribs were observed at doses without maternal toxicity. 
Isto tako, opažena su kratka prekobrojna torakolumbalna rebra uz doze pri kojima nije bilo toksičnosti za majku.
The key secondary endpoints in Studies M0631 and M0634 were 
Ključne mjere sekundarnih ishoda u ispitivanjima M0631 i M0634 bile su:
Treatment Group 
Terapijska skupina
Lusutrombopag has low potential to inhibit CYP enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5), and to induce both CYP enzymes (CYP1A2, 2C9, and 3A4) and UGT enzymes (UGT1A2, 1A6, and 2B7). 
Lusutrombopag ima niski potencijal za inhibiciju enzima CYP-a (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A4/5) te za indukciju enzima CYP-a (CYP1A2, 2C9 i 3A4) i enzima UGT-a (UGT1A2, 1A6 i 2B7).
Do not breast-feed during treatment with Mulpleo, as it is not known if the medicine passes into milk. 
Nemojte dojiti za vrijeme liječenja lijekom Mulpleo jer nije poznato prelazi li ovaj lijek u majčino mlijeko.
Neither food (including high-fat and high-calorie diet) nor co-administration with calcium has a clinically meaningful effect on the pharmacokinetics of lusutrombopag. 
Ni hrana (uključujući visokokaloričnu prehranu s velikim udjelom masti) ni istodobna primjena s kalcijem nisu imali klinički značajan učinak na farmakokinetiku lusutrombopaga.
In rats, results indicated that lusutrombopag and its metabolites transfer to fetus via placenta. 
U štakora su rezultati pokazali da lusutrombopag i njegovi metaboliti prolaze preko posteljice u fetus.
Warnings and precautions Talk to your doctor: - if you are at risk of blood clots in your veins or arteries, or if you previously have had blood clots - if you have severe liver disease - if your spleen has been removed - if you are having interferon treatment. 
- ako je kod Vas prisutan rizik od nastanka krvnih ugrušaka u venama ili arterijama ili ako ste prije imali krvne ugruške - ako imate tešku bolest jetre - ako Vam je uklonjena slezena
Interferon preparations have been known to reduce platelet counts, therefore, this should be considered when co-administering lusutrombopag with interferon preparations. 
Poznato je da pripravci interferona smanjuju broj trombocita pa je to potrebno uzeti u obzir kad se lusutrombopag primjenjuje istodobno s pripravcima interferona.
Due to limited information available, the safety and efficacy of Mulpleo in patients with severe hepatic impairment (Child-Pugh class C) have not been established (see sections 4.4 and 5.1). 
Zbog ograničenosti dostupnih informacija, sigurnost i djelotvornost lijeka Mulpleo u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) nisu ustanovljene (vidjeti dijelove 4.4 i 5.1).
Mulpleo contains the active substance lusutrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists. 
Mulpleo sadrži djelatnu tvar lusutrombopag, koja pripada skupini lijekova pod nazivom agonisti trombopoetinskih receptora.
Pregnancy and breast-feeding Do not take Mulpleo if you are pregnant unless your doctor specifically recommends it. 
Nemojte uzimati Mulpleo ako ste trudni, osim ako Vam je to liječnik posebno preporučio.
This limited data suggested no abnormal pattern of platelet count rise in this subpopulation. 
Ovi ograničeni podaci nisu ukazali na poremećeni obrazac povećanja broja trombocita u ove podpopulacije.
Lusutrombopag was not genotoxic when tested in a bacterial reverse mutation test, a chromosomal aberration test with cultured Chinese hamster lung cells, or an in vivo micronucleus test with mouse bone marrow cells. 
Lusutrombopag nije bio genotoksičan kad je testiran testom bakterijske reverzne mutacije, testom kromosomske aberacije na uzgojenim stanicama pluća kineskog hrčka ili in vivo mikronukleusnim testom na stanicama koštane srži miša.
- The other ingredients are: - Tablet core: mannitol, microcrystalline cellulose, magnesium oxide, sodium lauryl sulfate, hydroxypropylcellulose, carmellose calcium and magnesium stearate - Film coating: hypromellose, titanium dioxide, triethyl citrate, talc and red-ferric oxide (E172) 
- Drugi sastojci su: - Jezgra tablete: manitol, mikrokristalična celuloza, magnezijev oksid, natrijev laurilsulfat, hidroksipropilceluloza, karmelozakalcij i magnezijev stearat - Film-ovojnica: hipromeloza, titanijev dioksid, trietilcitrat, talk i crveni željezov oksid (E172)
Geometric mean (%CV) other than for Tmax, which is median (range). 
n = 9 Geometrijska sredina (% koeficijenta varijacije) za sve osim Tmax, za koji je prikazan medijan (raspon).
The procedure should be performed from day 9 after the start of lusutrombopag treatment. 
Invazivni postupak provodi se od 9. dana po uvođenju liječenja lusutrombopagom.
In vitro studies revealed that CYP4 enzymes including CYP4A11 and partially CYP3A4 enzyme contributed to ω-oxidation to form 6-hydroxylated lusutrombopag. 
In vitro ispitivanja pokazala su da su ω-oksidaciji pridonijeli enzimi CYP4 uključujući CYP4A11 i djelomično enzim CYP3A4, pri čemu je nastao 6-hidroksilirani lusutrombopag.
Studies in animals have shown lusutrombopag is secreted in the milk of lactating rats (see section 5.3). 
Ispitivanja na životinjama pokazala su da se lusutrombopag izlučuje u mlijeko ženki štakora tijekom laktacije (vidjeti dio 5.3).